false2020Q3000147824212/3100014782422020-01-012020-09-300001478242dei:OtherAddressMember2020-01-012020-09-30xbrli:shares00014782422020-10-16iso4217:USD00014782422020-07-012020-09-3000014782422019-07-012019-09-3000014782422019-01-012019-09-30iso4217:USDxbrli:shares00014782422020-09-3000014782422019-12-3100014782422018-12-3100014782422019-09-300001478242us-gaap:CommonStockMember2019-12-310001478242us-gaap:TreasuryStockMember2019-12-310001478242us-gaap:AdditionalPaidInCapitalMember2019-12-310001478242us-gaap:RetainedEarningsMember2019-12-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001478242us-gaap:NoncontrollingInterestMember2019-12-310001478242us-gaap:CommonStockMember2020-01-012020-03-310001478242us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100014782422020-01-012020-03-310001478242us-gaap:TreasuryStockMember2020-01-012020-03-310001478242us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001478242us-gaap:RetainedEarningsMember2020-01-012020-03-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001478242us-gaap:CommonStockMember2020-03-310001478242us-gaap:TreasuryStockMember2020-03-310001478242us-gaap:AdditionalPaidInCapitalMember2020-03-310001478242us-gaap:RetainedEarningsMember2020-03-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001478242us-gaap:NoncontrollingInterestMember2020-03-3100014782422020-03-310001478242us-gaap:CommonStockMember2020-04-012020-06-300001478242us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000014782422020-04-012020-06-300001478242us-gaap:RetainedEarningsMember2020-04-012020-06-300001478242us-gaap:NoncontrollingInterestMember2020-04-012020-06-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001478242us-gaap:CommonStockMember2020-06-300001478242us-gaap:TreasuryStockMember2020-06-300001478242us-gaap:AdditionalPaidInCapitalMember2020-06-300001478242us-gaap:RetainedEarningsMember2020-06-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001478242us-gaap:NoncontrollingInterestMember2020-06-3000014782422020-06-300001478242us-gaap:CommonStockMember2020-07-012020-09-300001478242us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001478242us-gaap:NoncontrollingInterestMember2020-07-012020-09-300001478242us-gaap:RetainedEarningsMember2020-07-012020-09-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001478242us-gaap:CommonStockMember2020-09-300001478242us-gaap:TreasuryStockMember2020-09-300001478242us-gaap:AdditionalPaidInCapitalMember2020-09-300001478242us-gaap:RetainedEarningsMember2020-09-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001478242us-gaap:NoncontrollingInterestMember2020-09-300001478242us-gaap:CommonStockMember2018-12-310001478242us-gaap:TreasuryStockMember2018-12-310001478242us-gaap:AdditionalPaidInCapitalMember2018-12-310001478242us-gaap:RetainedEarningsMember2018-12-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001478242us-gaap:NoncontrollingInterestMember2018-12-310001478242us-gaap:CommonStockMember2019-01-012019-03-310001478242us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-3100014782422019-01-012019-03-310001478242us-gaap:TreasuryStockMember2019-01-012019-03-310001478242us-gaap:RetainedEarningsMember2019-01-012019-03-310001478242us-gaap:NoncontrollingInterestMember2019-01-012019-03-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001478242us-gaap:CommonStockMember2019-03-310001478242us-gaap:TreasuryStockMember2019-03-310001478242us-gaap:AdditionalPaidInCapitalMember2019-03-310001478242us-gaap:RetainedEarningsMember2019-03-310001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001478242us-gaap:NoncontrollingInterestMember2019-03-3100014782422019-03-310001478242us-gaap:CommonStockMember2019-04-012019-06-300001478242us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-3000014782422019-04-012019-06-300001478242us-gaap:TreasuryStockMember2019-04-012019-06-300001478242us-gaap:NoncontrollingInterestMember2019-04-012019-06-300001478242us-gaap:RetainedEarningsMember2019-04-012019-06-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001478242us-gaap:CommonStockMember2019-06-300001478242us-gaap:TreasuryStockMember2019-06-300001478242us-gaap:AdditionalPaidInCapitalMember2019-06-300001478242us-gaap:RetainedEarningsMember2019-06-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001478242us-gaap:NoncontrollingInterestMember2019-06-3000014782422019-06-300001478242us-gaap:CommonStockMember2019-07-012019-09-300001478242us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001478242us-gaap:TreasuryStockMember2019-07-012019-09-300001478242us-gaap:NoncontrollingInterestMember2019-07-012019-09-300001478242us-gaap:RetainedEarningsMember2019-07-012019-09-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001478242us-gaap:CommonStockMember2019-09-300001478242us-gaap:TreasuryStockMember2019-09-300001478242us-gaap:AdditionalPaidInCapitalMember2019-09-300001478242us-gaap:RetainedEarningsMember2019-09-300001478242us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001478242us-gaap:NoncontrollingInterestMember2019-09-30iqv:Employeeiqv:Country0001478242srt:MinimumMember2020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMembersrt:AmericasMember2020-07-012020-09-300001478242srt:AmericasMemberiqv:ResearchAndDevelopmentSolutionsMember2020-07-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AmericasMember2020-07-012020-09-300001478242srt:AmericasMember2020-07-012020-09-300001478242us-gaap:EMEAMemberiqv:TechnologyAndAnalyticsSolutionsMember2020-07-012020-09-300001478242us-gaap:EMEAMemberiqv:ResearchAndDevelopmentSolutionsMember2020-07-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:EMEAMember2020-07-012020-09-300001478242us-gaap:EMEAMember2020-07-012020-09-300001478242srt:AsiaPacificMemberiqv:TechnologyAndAnalyticsSolutionsMember2020-07-012020-09-300001478242srt:AsiaPacificMemberiqv:ResearchAndDevelopmentSolutionsMember2020-07-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AsiaPacificMember2020-07-012020-09-300001478242srt:AsiaPacificMember2020-07-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMember2020-07-012020-09-300001478242iqv:ResearchAndDevelopmentSolutionsMember2020-07-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMember2020-07-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMembersrt:AmericasMember2019-07-012019-09-300001478242srt:AmericasMemberiqv:ResearchAndDevelopmentSolutionsMember2019-07-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AmericasMember2019-07-012019-09-300001478242srt:AmericasMember2019-07-012019-09-300001478242us-gaap:EMEAMemberiqv:TechnologyAndAnalyticsSolutionsMember2019-07-012019-09-300001478242us-gaap:EMEAMemberiqv:ResearchAndDevelopmentSolutionsMember2019-07-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:EMEAMember2019-07-012019-09-300001478242us-gaap:EMEAMember2019-07-012019-09-300001478242srt:AsiaPacificMemberiqv:TechnologyAndAnalyticsSolutionsMember2019-07-012019-09-300001478242srt:AsiaPacificMemberiqv:ResearchAndDevelopmentSolutionsMember2019-07-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AsiaPacificMember2019-07-012019-09-300001478242srt:AsiaPacificMember2019-07-012019-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMember2019-07-012019-09-300001478242iqv:ResearchAndDevelopmentSolutionsMember2019-07-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMember2019-07-012019-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMembersrt:AmericasMember2020-01-012020-09-300001478242srt:AmericasMemberiqv:ResearchAndDevelopmentSolutionsMember2020-01-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AmericasMember2020-01-012020-09-300001478242srt:AmericasMember2020-01-012020-09-300001478242us-gaap:EMEAMemberiqv:TechnologyAndAnalyticsSolutionsMember2020-01-012020-09-300001478242us-gaap:EMEAMemberiqv:ResearchAndDevelopmentSolutionsMember2020-01-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:EMEAMember2020-01-012020-09-300001478242us-gaap:EMEAMember2020-01-012020-09-300001478242srt:AsiaPacificMemberiqv:TechnologyAndAnalyticsSolutionsMember2020-01-012020-09-300001478242srt:AsiaPacificMemberiqv:ResearchAndDevelopmentSolutionsMember2020-01-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AsiaPacificMember2020-01-012020-09-300001478242srt:AsiaPacificMember2020-01-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMember2020-01-012020-09-300001478242iqv:ResearchAndDevelopmentSolutionsMember2020-01-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMember2020-01-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMembersrt:AmericasMember2019-01-012019-09-300001478242srt:AmericasMemberiqv:ResearchAndDevelopmentSolutionsMember2019-01-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AmericasMember2019-01-012019-09-300001478242srt:AmericasMember2019-01-012019-09-300001478242us-gaap:EMEAMemberiqv:TechnologyAndAnalyticsSolutionsMember2019-01-012019-09-300001478242us-gaap:EMEAMemberiqv:ResearchAndDevelopmentSolutionsMember2019-01-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:EMEAMember2019-01-012019-09-300001478242us-gaap:EMEAMember2019-01-012019-09-300001478242srt:AsiaPacificMemberiqv:TechnologyAndAnalyticsSolutionsMember2019-01-012019-09-300001478242srt:AsiaPacificMemberiqv:ResearchAndDevelopmentSolutionsMember2019-01-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMembersrt:AsiaPacificMember2019-01-012019-09-300001478242srt:AsiaPacificMember2019-01-012019-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMember2019-01-012019-09-300001478242iqv:ResearchAndDevelopmentSolutionsMember2019-01-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMember2019-01-012019-09-30iqv:Customerxbrli:pure00014782422020-10-012020-09-300001478242us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300001478242us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300001478242iqv:DepreciationAndAmortizationAndInterestMember2020-07-012020-09-300001478242iqv:DepreciationAndAmortizationAndInterestMember2019-07-012019-09-300001478242us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300001478242us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300001478242iqv:DepreciationAndAmortizationAndInterestMember2020-01-012020-09-300001478242iqv:DepreciationAndAmortizationAndInterestMember2019-01-012019-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMember2019-12-310001478242iqv:ResearchAndDevelopmentSolutionsMember2019-12-310001478242iqv:ContractSalesAndMedicalSolutionsMember2019-12-310001478242iqv:TechnologyAndAnalyticsSolutionsMember2020-09-300001478242iqv:ResearchAndDevelopmentSolutionsMember2020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMember2020-09-300001478242iqv:OtherCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-09-300001478242iqv:OtherCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2019-12-310001478242us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberiqv:OtherAssetsAndLiabilitiesMember2020-09-300001478242us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberiqv:OtherAssetsAndLiabilitiesMember2019-12-310001478242us-gaap:InterestRateSwapMemberus-gaap:OtherLiabilitiesMemberus-gaap:NondesignatedMember2020-09-300001478242us-gaap:InterestRateSwapMemberus-gaap:OtherLiabilitiesMemberus-gaap:NondesignatedMember2019-12-310001478242us-gaap:ForeignExchangeForwardMember2020-07-012020-09-300001478242us-gaap:ForeignExchangeForwardMember2019-07-012019-09-300001478242us-gaap:ForeignExchangeForwardMember2020-01-012020-09-300001478242us-gaap:ForeignExchangeForwardMember2019-01-012019-09-300001478242us-gaap:InterestRateContractMember2020-07-012020-09-300001478242us-gaap:InterestRateContractMember2019-07-012019-09-300001478242us-gaap:InterestRateContractMember2020-01-012020-09-300001478242us-gaap:InterestRateContractMember2019-01-012019-09-300001478242iqv:FairValueInputsLevel1AndLevel2Member2020-09-300001478242iqv:FairValueInputsLevel1AndLevel2Member2019-12-310001478242us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001478242us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300001478242us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300001478242us-gaap:FairValueMeasurementsRecurringMember2020-09-300001478242iqv:ContingentConsiderationMember2019-12-310001478242iqv:ContingentConsiderationMember2018-12-310001478242iqv:ContingentConsiderationMember2020-01-012020-09-300001478242iqv:ContingentConsiderationMember2019-01-012019-09-300001478242iqv:ContingentConsiderationMember2020-09-300001478242iqv:ContingentConsiderationMember2019-09-300001478242iqv:RevenueTargetMember2020-09-300001478242iqv:RevenueTargetMembersrt:MinimumMember2020-09-300001478242iqv:RevenueTargetMembersrt:MaximumMember2020-09-300001478242iqv:EBITDATargetMember2020-09-300001478242srt:MinimumMemberiqv:EBITDATargetMember2020-09-300001478242iqv:EBITDATargetMembersrt:MaximumMember2020-09-300001478242iqv:CustomerTargetMember2020-09-300001478242iqv:CustomerTargetMembersrt:MinimumMember2020-09-300001478242iqv:CustomerTargetMembersrt:MaximumMember2020-09-300001478242iqv:USDRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-09-300001478242iqv:USDRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2020-01-012020-09-300001478242iqv:USDRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:AccountsReceivableFinancingFacilityMemberus-gaap:LineOfCreditMember2020-09-300001478242iqv:AccountsReceivableFinancingFacilityMemberus-gaap:LineOfCreditMember2020-01-012020-09-300001478242iqv:AccountsReceivableFinancingFacilityMemberus-gaap:LineOfCreditMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-30iso4217:GBP0001478242iqv:BankCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-300001478242iqv:BankCreditFacilityMemberus-gaap:LineOfCreditMember2020-01-012020-09-300001478242iqv:BankCreditFacilityMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermALoanMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermALoanMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermALoanMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredTermLoanAAt275PercentMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermLoanAAt275PercentMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermLoanAAt275PercentMemberus-gaap:DebtInstrumentRedemptionPeriodOneMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredTermALoanMembercurrency:EURus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermALoanMembercurrency:EURus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermALoanMembercurrency:EURus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:EURus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:EURus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:EURus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:SeniorSecuredAdditionalTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242iqv:SeniorSecuredAdditionalTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242iqv:SeniorSecuredAdditionalTermBLoanMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242currency:EURiqv:SeniorSecuredAdditionalTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242currency:EURiqv:SeniorSecuredAdditionalTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242currency:EURiqv:SeniorSecuredAdditionalTermBLoanMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:RevolvingCreditFacilityMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:RevolvingCreditFacilityMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:RevolvingCreditFacilityMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242us-gaap:RevolvingCreditFacilityMembercurrency:JPYus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-09-300001478242us-gaap:RevolvingCreditFacilityMembercurrency:JPYus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242us-gaap:RevolvingCreditFacilityMembercurrency:JPYus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:DebtInstrumentRedemptionPeriodSixMemberus-gaap:SeniorNotesMembercurrency:USDiqv:FivePointZeroPercentageSeniorNotesMember2020-09-300001478242us-gaap:SeniorNotesMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodFourMemberiqv:FivePointZeroPercentageSeniorNotesMember2020-09-300001478242iqv:DebtInstrumentRedemptionPeriodSixMemberus-gaap:SeniorNotesMembercurrency:USDiqv:FivePointZeroPercentageSeniorNotesMember2019-12-310001478242us-gaap:SeniorNotesMembercurrency:USDus-gaap:DebtInstrumentRedemptionPeriodFourMemberiqv:FivePointZeroPercentageSeniorNotesMember2019-12-310001478242currency:EURus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2020-09-300001478242currency:EURus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2020-09-300001478242currency:EURus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2019-12-310001478242currency:EURus-gaap:SeniorNotesMemberiqv:ThreePointTwoFivePercentageSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2020-09-300001478242currency:EURus-gaap:SeniorNotesMemberiqv:ThreePointTwoFivePercentageSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2019-12-310001478242iqv:ThreePointFivePercentageSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:EURus-gaap:SeniorNotesMember2020-09-300001478242iqv:ThreePointFivePercentageSeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembercurrency:EURus-gaap:SeniorNotesMember2019-12-310001478242currency:EURus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointTwoFivePercentageSeniorNotesMember2020-09-300001478242currency:EURus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointTwoFivePercentageSeniorNotesMember2019-12-310001478242currency:EURus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2019-12-310001478242us-gaap:DebtInstrumentRedemptionPeriodFiveMemberiqv:AccountsReceivableFinancingFacilityMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001478242us-gaap:DebtInstrumentRedemptionPeriodFiveMemberiqv:AccountsReceivableFinancingFacilityMembercurrency:USDus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310001478242iqv:BankCreditFacilityMember2020-01-012020-09-300001478242iqv:SeniorSecuredCreditFacilitiesMember2020-09-300001478242us-gaap:StandbyLettersOfCreditMember2020-09-300001478242iqv:TLA2LoansMemberus-gaap:SecuredDebtMember2020-03-110001478242iqv:TLA2LoansMemberus-gaap:SecuredDebtMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-03-302020-03-300001478242iqv:TLA2LoansMemberus-gaap:SecuredDebtMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-03-302020-03-300001478242iqv:TLA2LoansMemberus-gaap:SecuredDebtMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-03-302020-03-300001478242iqv:TLA2LoansMemberus-gaap:SecuredDebtMember2020-03-302020-03-30iso4217:EUR0001478242us-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2020-06-240001478242us-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMembersrt:MaximumMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2020-06-242020-06-240001478242srt:MinimumMemberus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMemberiqv:TwoPointEightSevenFivePercentageSeniorNotesMember2020-06-242020-06-240001478242iqv:ThreePointFivePercentageSeniorNotesMembercurrency:EURus-gaap:SeniorNotesMemberiqv:DebtInstrumentRedemptionPeriodSevenMember2020-06-240001478242iqv:SecondaryPublicOfferingMemberiqv:EquityRepurchaseUnderRepurchaseProgramMember2020-01-012020-09-300001478242iqv:RepurchasedFromCompanyStockholdersMemberiqv:EquityRepurchaseUnderRepurchaseProgramMember2020-01-012020-09-300001478242iqv:EquityRepurchaseUnderRepurchaseProgramMember2020-09-300001478242iqv:SeveranceAndRelatedCostsMember2019-12-310001478242us-gaap:FacilityClosingMember2019-12-310001478242iqv:SeveranceAndRelatedCostsMember2020-01-012020-09-300001478242us-gaap:FacilityClosingMember2020-01-012020-09-300001478242iqv:SeveranceAndRelatedCostsMember2020-09-300001478242us-gaap:FacilityClosingMember2020-09-300001478242us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001478242us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001478242us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001478242us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300001478242us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300001478242us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300001478242us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300001478242us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300001478242us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:SalesMember2020-07-012020-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:SalesMember2019-07-012019-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:SalesMember2020-01-012020-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:SalesMember2019-01-012019-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-07-012020-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-07-012019-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-300001478242us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-01-012019-09-30iqv:Segment0001478242iqv:TechnologyAndAnalyticsSolutionsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001478242iqv:TechnologyAndAnalyticsSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-09-300001478242iqv:ResearchAndDevelopmentSolutionsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001478242iqv:ResearchAndDevelopmentSolutionsMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-300001478242iqv:ResearchAndDevelopmentSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001478242iqv:ResearchAndDevelopmentSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001478242iqv:ContractSalesAndMedicalSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-09-300001478242us-gaap:CorporateNonSegmentMember2020-07-012020-09-300001478242us-gaap:CorporateNonSegmentMember2019-07-012019-09-300001478242us-gaap:CorporateNonSegmentMember2020-01-012020-09-300001478242us-gaap:CorporateNonSegmentMember2019-01-012019-09-300001478242us-gaap:PerformanceSharesMember2020-07-012020-09-300001478242us-gaap:PerformanceSharesMember2019-07-012019-09-300001478242us-gaap:PerformanceSharesMember2020-01-012020-09-300001478242us-gaap:PerformanceSharesMember2019-01-012019-09-300001478242us-gaap:StockCompensationPlanMember2020-07-012020-09-300001478242us-gaap:StockCompensationPlanMember2019-07-012019-09-300001478242us-gaap:StockCompensationPlanMember2020-01-012020-09-300001478242us-gaap:StockCompensationPlanMember2019-01-012019-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 10-Q
_________________________________________________________
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to             .
Commission File Number: 001-35907
_________________________________________________________
IQVIA HOLDINGS INC.
IQV-20200930_G1.JPG
(Exact name of registrant as specified in its charter)
_________________________________________________________
Delaware 27-1341991
(State or other jurisdiction of
incorporation or organization) 		(I.R.S. Employer
Identification Number)
4820 Emperor Blvd., Durham, North Carolina 27703
and
83 Wooster Heights Road, Danbury, Connecticut 06810
(Address of principal executive offices and Zip Code)
(919) 998-2000 and (203) 448-4600
(Registrant’s telephone number, including area code)
_________________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x    No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes x    No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No x
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Each Exchange on which Registered
Common Stock, par value $0.01 per share
IQV
New York Stock Exchange
Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date.
Class
Number of Shares Outstanding
Common Stock $0.01 par value 191,725,778 shares outstanding as of October 16, 2020


Table of contents
IQVIA HOLDINGS INC.
FORM 10-Q
TABLE OF CONTENTS
Page
3
3
3
4
5
6
7
9
21
33
33
34
34
34
34
36
37

2
Table of contents
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
(in millions, except per share data)
2020 2019 2020 2019
Revenues $ 2,786  $ 2,769  $ 8,061  $ 8,193 
Costs of revenue, exclusive of depreciation and amortization 1,800  1,852  5,328  5,399 
Selling, general and administrative expenses 460  395  1,298  1,250 
Depreciation and amortization 319  299  943  888 
Restructuring costs 20  19  50  45 
Income from operations 187  204  442  611 
Interest income (1) (3) (4) (7)
Interest expense 100  114  314  338 
Loss on extinguishment of debt —  24  12  24 
Other income, net (14) —  (59) — 
Income before income taxes and equity in earnings of unconsolidated affiliates 102  69  179  256 
Income tax (benefit) expense (3) (1) 9  48 
Income before equity in earnings of unconsolidated affiliates 105  70  170  208 
Equity in earnings (loss) of unconsolidated affiliates 3  (1) 8  (1)
Net income 108  69  178  207 
Net income attributable to non-controlling interests (7) (12) (18) (32)
Net income attributable to IQVIA Holdings Inc. $ 101  $ 57  $ 160  $ 175 
Earnings per share attributable to common stockholders:
Basic $ 0.53  $ 0.29  $ 0.84  $ 0.89 
Diluted $ 0.52  $ 0.29  $ 0.82  $ 0.87 
Weighted average common shares outstanding:
Basic 191.3  194.5  191.3  195.9 
Diluted 194.9  199.0 194.9  200.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(unaudited)
Three Months Ended
September 30, 		Nine Months Ended
September 30,
(in millions) 2020 2019 2020 2019
Net income $ 108  $ 69  $ 178  $ 207 
Comprehensive income (loss) adjustments:
Unrealized (losses) gains on derivative instruments, net of income tax (benefit) expense of $(8), $(2), $(11), $(7)
(1) (5) (33) (23)
Foreign currency translation, net of income tax expense (benefit) of $(54), $57, $(83), $65
130  (162) 20  (131)
Reclassification adjustments:
Losses (gains) on derivative instruments included in net income, net of income tax expense (benefit) of $1, $—, $2, $(1)
2  2  6  (2)
Comprehensive income (loss)
239  (96) 171  51 
Comprehensive income attributable to non-controlling interests
(11) (9) (17) (29)
Comprehensive income (loss) attributable to IQVIA Holdings Inc.
$ 228  $ (105) $ 154  $ 22 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share data) September 30, 2020 December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents $ 1,464  $ 837 
Trade accounts receivable and unbilled services, net 2,414  2,582 
Prepaid expenses 165  138 
Income taxes receivable 78  56 
Investments in debt, equity and other securities 79  62 
Other current assets and receivables 445  451 
Total current assets 4,645  4,126 
Property and equipment, net 452  458 
Operating lease right-of-use assets 490  496 
Investments in debt, equity and other securities 78  65 
Investments in unconsolidated affiliates 85  87 
Goodwill 12,363  12,159 
Other identifiable intangibles, net 5,222  5,514 
Deferred income taxes 125  119 
Deposits and other assets 377  227 
Total assets $ 23,837  $ 23,251 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 2,461  $ 2,512 
Unearned income 1,188  1,014 
Income taxes payable 101  108 
Current portion of long-term debt 144  100 
Other current liabilities 245  211 
Total current liabilities 4,139  3,945 
Long-term debt 12,195  11,545 
Deferred income taxes 429  646 
Operating lease liabilities 387  396 
Other liabilities 580  456 
Total liabilities 17,730  16,988 
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized at September 30, 2020 and December 31, 2019, $0.01 par value, 254.5 shares issued and 191.7 shares outstanding at September 30, 2020; 253.0 shares issued and 192.3 shares outstanding at December 31, 2019
11,070  11,049 
Retained earnings 1,158  998 
Treasury stock, at cost, 62.8 and 60.7 shares at September 30, 2020 and December 31, 2019, respectively
(6,065) (5,733)
Accumulated other comprehensive loss (317) (311)
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,846  6,003 
Non-controlling interests 261  260 
Total stockholders’ equity 6,107  6,263 
Total liabilities and stockholders’ equity $ 23,837  $ 23,251 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
Nine Months Ended September 30,
(in millions)
2020 2019
Operating activities:
Net income
$ 178  $ 207 
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization
943  888 
Amortization of debt issuance costs and discount
13  10 
Stock-based compensation
69  87 
(Earnings) loss from unconsolidated affiliates (8) 1 
Gain on investments, net (17) — 
Benefit from deferred income taxes
(160) (154)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income
328  (167)
Change in other operating assets and liabilities
(137) (38)
Net cash provided by operating activities
1,209  834 
Investing activities:
Acquisition of property, equipment and software
(440) (445)
Acquisition of businesses, net of cash acquired
(118) (461)
Purchases of marketable securities, net
(8) (2)
Investments in unconsolidated affiliates, net of payments received
8  3 
Investments in equity securities
(2) (10)
Other
—  5 
Net cash used in investing activities
(560) (910)
Financing activities:
Proceeds from issuance of debt
1,591  1,900 
Payment of debt issuance costs
(33) (47)
Repayment of debt and principal payments on capital lease obligations
(792) (875)
Proceeds from revolving credit facility
1,250  1,710 
Repayment of revolving credit facility
(1,610) (1,930)
(Payments) proceeds related to employee stock option plans (43) 15 
Repurchase of common stock
(346) (679)
Distributions to non-controlling interests, net (16) (6)
Contingent consideration and deferred purchase price payments
(20) (21)
Net cash (used in) provided by financing activities (19) 67 
Effect of foreign currency exchange rate changes on cash
(3) (19)
Increase (decrease) in cash and cash equivalents 627  (28)
Cash and cash equivalents at beginning of period
837  891 
Cash and cash equivalents at end of period
$ 1,464  $ 863 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in millions) Common
Stock
Shares 		Treasury
Stock
Shares 		Common
Stock 		Additional
Paid-In
Capital 		Retained Earnings Treasury
Stock 		Accumulated
Other
Comprehensive
(Loss) Income 		Non-
controlling
Interests 		Total
Balance, December 31, 2019 253.0  (60.7) $ 3  $ 11,046  $ 998  $ (5,733) $ (311) $ 260  $ 6,263 
Issuance of common stock 0.8  —  —  (44) —  —  —  —  (44)
Repurchase of common stock —  (2.1) —  —  —  (332) —  —  (332)
Stock-based compensation —  —  —  7  —  —  —  —  7 
Distributions to non-controlling interests, net —  —  —  —  —  —  —  (5) (5)
Net income —  —  —  —  82  —  —  9  91 
Unrealized losses on derivative instruments, net of tax —  —  —  —  —  —  (39) —  (39)
Foreign currency translation, net of tax —  —  —  —  —  —  (151) (4) (155)
Reclassification adjustments, net of tax —  —  —  —  —  —  16  —  16 
Balance, March 31, 2020 253.8  (62.8) 3  11,009  1,080  (6,065) (485) 260  5,802 
Issuance of common stock 0.3  —  —  1  —  —  —  —  1 
Stock-based compensation —  —  —  30  —  —  —  —  30 
Net (loss) income —  —  —  —  (23) —  —  2  (21)
Unrealized losses on derivative instruments, net of tax
—  —  —  —  —  —  7  —  7 
Foreign currency translation, net of tax —  —  —  —  —  —  46  (1) 45 
Reclassification adjustments, net of tax —  —  —  —  —  —  (12) —  (12)
Balance, June 30, 2020 254.1  (62.8) $ 3  $ 11,040  $ 1,057  $ (6,065) $ (444) $ 261  $ 5,852 
Issuance of common stock 0.4  —  —  (3) —  —  —  —  (3)
Stock-based compensation —  —  —  30  —  —  —  —  30 
Distributions to non-controlling interests, net —  —  —  —  —  —  —  (11) (11)
Net income —  —  —  —  101  —  —  7  108 
Unrealized losses on derivative instruments, net of tax
—  —  —  —  —  —  (1) —  (1)
Foreign currency translation, net of tax —  —  —  —  —  —  126  4  130 
Reclassification adjustments, net of tax —  —  —  —  —  —  2  —  2 
Balance, September 30, 2020 $ 254.5  $ (62.8) $ 3  $ 11,067  $ 1,158  $ (6,065) $ (317) $ 261  $ 6,107 

7
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in millions)
Common
Stock
Shares
Treasury
Stock
Shares
Common
Stock
Additional
Paid-In
Capital
Retained Earnings
Treasury
Stock
Accumulated
Other
Comprehensive
Income (Loss)
Non-
controlling
Interests
Total
Balance, December 31, 2018 251.5  (54) $ 3  $ 10,898  $ 807  $ (4,770) $ (224) $ 240  $ 6,954 
Issuance of common stock 0.7  —  —  5  —  —  —  —  5 
Repurchase of common stock —  (1) —  —  —  (145) —  —  (145)
Stock-based compensation —  —  —  21  —  —  —  —  21 
Net income —  —  —  —  58  —  —  9  67 
Unrealized losses on derivative instruments, net of tax —  —  —  —  —  —  (5) —  (5)
Foreign currency translation, net of tax —  —  —  —  —  —  (32) 1  (31)
Reclassification adjustments, net of tax —  —  —  —  —  —  (1) —  (1)
Balance, March 31, 2019 252.2  (55.0) $ 3  $ 10,924  $ 865  $ (4,915) $ (262) $ 250  $ 6,865 
Issuance of common stock 0.4  —  —  8  —  —  —  —  8 
Repurchase of common stock —  (1.8) —  —  —  (236) —  —  (236)
Stock-based compensation —  —  —  29  —  —  —  —  29 
Distributions to non-controlling interests —  —  —  —  —  —  —  (2) (2)
Net income —  —  —  —  60  —  —  11  71 
Unrealized losses on derivative instruments, net of tax —  —  —  —  —  —  (13) —  (13)
Foreign currency translation, net of tax —  —  —  —  —  —  63  (1) 62 
Reclassification adjustments, net of tax —  —  —  —  —  —  (3) —  (3)
Balance, June 30, 2019 252.6  (56.8) $ 3  $ 10,961  $ 925  $ (5,151) $ (215) $ 258  $ 6,781 
Issuance of common stock 0.2  —  —  (4) —  —  —  —  (4)
Repurchase of common stock —  (2) —  —  —  (313) —  —  (313)
Balance, Stock-based compensation —  —  —  30  —  —  —  —  30 
Distributions to non-controlling interests —  —  —  —  —  —  —  (4) (4)
Net income —  —  —  —  57  —  —  12  69 
Unrealized losses on derivative instruments, net of tax —  —  —  —  —  —  (5) —  (5)
Foreign currency translation, net of tax —  —  —  —  —  —  (159) (3) (162)
Reclassification adjustments, net of tax —  —  —  —  —  —  2  —  2 
Balance, September 30, 2019 252.8  (58.8) 3  10,987  982  (5,464) (377) 263  6,394 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
Table of contents
IQVIA HOLDINGS INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
1. Summary of Significant Accounting Policies
The Company
IQVIA Holdings Inc. (together with its subsidiaries, the “Company” or “IQVIA”) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. With approximately 68,000 employees, IQVIA conducts business in more than 100 countries.
Unaudited Interim Financial Information
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Additionally, the outbreak of the novel coronavirus, or COVID-19, and the various governmental, industry and consumer actions related thereto, could have a material and adverse effect on our business, financial condition and results of operations. These effects, which largely depend on future developments that cannot be accurately predicted and are uncertain, could include a negative impact on the availability of our key personnel, temporary closures of our facilities or the facilities of our business partners, customers, suppliers, third party service providers or other vendors, an increased risk of customer defaults or delays in payments or purchasing decisions, and the interruption of domestic and global supply chains, distribution channels, liquidity and capital or financial markets. As COVID-19 continues to spread, we have and may continue to experience disruptions that could severely impact our business. As such, the results for the three and nine months ended September 30, 2020 may not be indicative of results for the full year.
Recently Issued Accounting Standards
Accounting pronouncements adopted
In August 2018, the FASB issued new accounting guidance that clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements.
In August 2018, the FASB issued new accounting guidance that modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new accounting guidance also modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements.
9
In January 2017, the FASB issued new accounting guidance that simplifies the measurement of goodwill by eliminating the step two impairment test. Step two measures a goodwill impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The new guidance requires a comparison of the Company’s fair value of a reporting unit with the carrying amount and the Company is required to recognize an impairment charge for the amount by which the carrying amount exceeds the fair value. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements.
In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company's assessment of historical losses, client's creditworthiness and the fact that the Company's trade receivables are short term in duration.
Accounting pronouncements being evaluated
In March 2020, the FASB issued new accounting guidance that provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The new accounting guidance is effective for the Company as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of this new accounting guidance on its credit arrangements and derivatives that reference LIBOR. The Company does not expect the new accounting guidance to have a material effect on the Company’s consolidated financial statements.
In January 2020, the FASB issued new accounting guidance that states any equity security transitioning from the alternative method of accounting to the equity method, or vice versa, due to an observable transaction, will be remeasured immediately before the transition. In addition, the new accounting guidance clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles before settlement or exercise. The new accounting guidance will be effective for the Company on January 1, 2021 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.
In December 2019, the FASB issued new accounting guidance to clarify and simplify the accounting for income taxes. Changes under the new guidance includes eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new accounting guidance will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.

2. Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2020 and 2019:
Three Months Ended September 30, 2020
(in millions)
Technology &
Analytics Solutions
Research &
Development Solutions
Contract Sales &
Medical Solutions
Total
Revenues:
Americas
$ 599  $ 628  $ 76  $ 1,303 
Europe and Africa
457  411  44  912 
Asia-Pacific
151  361  59  571 
Total revenues
$ 1,207  $ 1,400  $ 179  $ 2,786 

10
Three Months Ended September 30, 2019
(in millions)
Technology &
Analytics Solutions
Research &
Development Solutions
Contract Sales &
Medical Solutions
Total
Revenues:
Americas
$ 580  $ 726  $ 104  $ 1,410 
Europe and Africa
369  394  48  811 
Asia-Pacific
146  346  56  548 
Total revenues
$ 1,095  $ 1,466  $ 208  $ 2,769 

Nine Months Ended September 30, 2020
(in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total
Revenues:
Americas $ 1,747  $ 1,826  $ 247  $ 3,820 
Europe and Africa 1,254  1,214  134  2,602 
Asia-Pacific 432  1,036  171  1,639 
Total revenues $ 3,433  $ 4,076  $ 552  $ 8,061 

Nine Months Ended September 30, 2019
(in millions) Technology &
Analytics Solutions 		Research &
Development Solutions 		Contract Sales &
Medical Solutions 		Total
Revenues:
Americas $ 1,722  $ 2,009  $ 298  $ 4,029 
Europe and Africa 1,128  1,298  148  2,574 
Asia-Pacific 422  1,010  158  1,590 
Total revenues $ 3,272  $ 4,317  $ 604  $ 8,193 
No customer accounted for 10% or more of consolidated revenues for the three and nine months ended September 30, 2020 or 2019.
Transaction Price Allocated to the Remaining Performance Obligations
As of September 30, 2020, approximately $23.6 billion of revenue is expected to be recognized in the future from remaining performance obligations. The Company expects to recognize revenue on approximately 30% of these remaining performance obligations over the next 12 months, with the balance recognized thereafter. The customer contract transaction price allocated to the remaining performance obligations differs from backlog in that it does not include wholly unperformed contracts under which the customer has a unilateral right to cancel the arrangement.
3. Trade Accounts Receivable, Unbilled Services and Unearned Income
Trade accounts receivables and unbilled services consist of the following:
(in millions)
September 30, 2020 December 31, 2019
Trade accounts receivable:
Billed
$ 1,152  $ 1,312 
Unbilled services
1,292  1,286 
Trade accounts receivable and unbilled services
2,444  2,598 
Allowance for doubtful accounts
(30) (16)
Trade accounts receivable and unbilled services, net
$ 2,414  $ 2,582 
11
Unbilled services and unearned income were as follows:
(in millions) September 30, 2020 December 31, 2019
Change
Unbilled services
$ 1,292  $ 1,286  $ 6 
Unearned income
(1,188) (1,014) (174)
Net balance
$ 104  $ 272  $ (168)
Unbilled services, which is comprised of approximately 60% of unbilled receivables and 40% of contract assets as of September 30, 2020, increased by $6 million as compared to December 31, 2019. Contract assets are unbilled services for which invoicing is based on the timing of certain milestones related to service contracts for clinical research whereas unbilled receivables are billable upon the passage of time. Unearned income increased by $174 million over the same period resulting in a decrease of $168 million in the net balance of unbilled services and unearned income between December 31, 2019 and September 30, 2020. The change in the net balance is driven by the difference in timing of revenue recognition in accordance with ASC 606, Revenue from Contracts with Customers, related to the Company’s Research & Development Solutions contracts (which is based on the percentage of costs incurred) versus the timing of invoicing, which is based on certain milestones.

Bad debt expense recognized on the Company’s receivables and unbilled services was not material for the three and nine months ended September 30, 2020 and 2019.
4. Leases
The Company has operating leases for corporate offices, datacenters, motor vehicles and certain equipment, many of which contain renewal and escalation clauses. These operating leases expire at various dates through 2029 with options to cancel certain leases at various intervals. The Company also has finance leases for office and lab spaces that expire in 2044. Based on the timing of payments on the finance leases the cash flow impact is not material for the three and nine months ended September 30, 2020. In determining the lease term at lease commencement, the Company includes the noncancellable term and the periods which the Company deems it is reasonably certain to exercise or not to exercise a renewal or cancellation option.
The components of lease expense were as follows:
(in millions) Classification Three Months Ended September 30, 2020 Three Months Ended September 30, 2019
Operating lease cost (1)
Selling, general and administrative expenses $ 49  $ 48 
Finance lease cost (1)
Depreciation and amortization, and Interest expense 3  — 
Total lease cost $ 52  $ 48 


(in millions) Classification Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019
Operating lease cost (1)
Selling, general and administrative expenses $ 151  $ 143 
Finance lease cost (1)
Depreciation and amortization, and Interest expense 4  — 
Total lease cost $ 155  $ 143 
(1)Includes variable lease costs, which are immaterial.
12
Other information related to leases was as follows:
(in millions) Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019
Supplemental Cash Flow:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases $ 147  $ 147 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases $ 92  $ 62 
Finance leases $ 119  $ — 
Weighted Average Remaining Lease Term:
Operating leases 4.65 years 4.90 years
Finance leases 24.25 years — 
Weighted Average Discount Rate:
Operating leases 4.04  % 4.26  %
Finance leases 3.18  % — 
Future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows:
(in millions) Operating Leases Finance Leases
Remainder of 2020 $ 44  $ — 
2021 153  — 
2022 128  6 
2023 100  6 
2024 70  6 
2025 56  6 
Thereafter 44  159 
Total future minimum lease payments 595  183 
Less imputed interest (54) (63)
Total $ 541  $ 120 
Reported as of September 30, 2020:
Other current liabilities $ 154  $ — 
Operating lease liabilities 387  — 
Other liabilities — 120
Total $ 541  $ 120 

5. Goodwill
The following is a summary of goodwill by reportable segment for the nine months ended September 30, 2020:
(in millions)
Technology & Analytics Solutions
Research & Development Solutions
Contract Sales & Medical Solutions
Consolidated
Balance as of December 31, 2019 $ 10,374  $ 1,646  $ 139  $ 12,159 
Business combinations
84  —  —  84 
Impact of foreign currency fluctuations and other
155  (39) 4  120 
Balance as of September 30, 2020 $ 10,613  $ 1,607  $ 143  $ 12,363 



13
6. Derivatives
The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table:

(in millions)
Balance Sheet Classification
September 30, 2020 December 31, 2019
Assets
Liabilities
Notional
Assets
Liabilities
Notional
Derivatives designated as hedging instruments:
Foreign exchange forward contracts
Other current assets and liabilities
$ 1  $ 1  $ 93  $ 4  $ —  $ 148 
Interest rate swaps
Other assets and liabilities
—  59  1,800  —  27  875 
Derivatives not designated as hedging instruments:
Interest rate swaps
Other liabilities
—  1  340  —  3  325 
Total derivatives
$ 1  $ 61  $ 4  $ 30 
The effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table:
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Foreign exchange forward contracts
$ 2  $ (1) $ (4) $ (5)
Interest rate derivatives
1  (3) (32) (27)
Total
$ 3  $ (4) $ (36) $ (32)
The amount of foreign exchange losses related to the net investment hedge included in the cumulative translation adjustment component of accumulated other comprehensive loss (“AOCI”) for the nine months ended September 30, 2020 was $273 million.
7. Fair Value Measurements
The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
•Level 1 — Quoted prices in active markets for identical assets or liabilities.
•Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
•Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

14
The carrying values of cash, cash equivalents, accounts receivable and accounts payable approximated their fair values at September 30, 2020 and December 31, 2019 due to their short-term nature. At September 30, 2020 and December 31, 2019, the fair value of total debt approximated $12,443 million and $11,925 million, respectively, as determined under Level 1 and Level 2 measurements for these financial instruments.
Recurring Fair Value Measurements
The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of September 30, 2020:
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Marketable securities 105  $ —  $ —  $ 105 
Derivatives —  $ 1  —  1 
Total $ 105  $ 1  $ —  $ 106 
Liabilities:
Derivatives $ —  $ 61  $ —  $ 61 
Contingent consideration —  —  108  108 
Total $ —  $ 61  $ 108  $ 169 
Below is a summary of the valuation techniques used in determining fair value:
Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held.
Derivatives — Derivatives consist of foreign exchange contracts and interest rate swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates or using other observable inputs. The fair value of the interest rate swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread.
Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include various financial metrics (revenue performance targets and operating forecasts) and the probability of achieving the specific targets.
The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30:
Contingent Consideration
(in millions)
2020 2019
Balance as of January 1
$ 113  $ 123 
Business combinations
32  41 
Contingent consideration paid
(22) (44)
Revaluations included in earnings and foreign currency translation adjustments
(15) (7)
Balance as of September 30 $ 108  $ 113 
The Company used the following key assumptions when estimating the fair value of contingent considerations:
Unobservable Input Weighted average probability of target achievement Range of potential payment
Revenue target 89%
0%-100%
EBITDA target 96%
0%-100%
Operational target 95%
0%-100%

15
The current portion of contingent consideration is included within accrued expenses and the long-term portion is included within other liabilities on the accompanying condensed consolidated balance sheets. Revaluations of the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. A change in significant unobservable inputs above could result in a significantly higher or lower fair value measurement of contingent consideration.
8. Credit Arrangements
The following is a summary of the Company’s revolving credit facilities at September 30, 2020:
Facility
Interest Rates
$1,500 million (revolving credit facility)
LIBOR in the relevant currency borrowed plus a margin of 1.50% at September 30, 2020
$25 million (receivables financing facility)
LIBOR Market Index Rate (0.15% at September 30, 2020) plus 0.90%
£10 million (approximately $13 million) (general banking facility)
Bank’s base rate of 0.10% at September 30, 2020 plus 1%
The following table summarizes the Company’s debt at the dates indicated:
(in millions) September 30, 2020 December 31, 2019
Senior Secured Credit Facilities:
Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 1.72%
$ 739  $ 770 
Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75%
778  — 
Term A Loan due 2023—Euro LIBOR at average floating rates of 1.50%
388  387 
Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 1.90%
535  535 
Term B Loan due 2024—Euro LIBOR at average floating rates of 2.00%
1,354  1,306 
Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.90%
728  733 
Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.97%
929  936 
Term B Loan due 2025—Euro LIBOR at average floating rates of 2.00%
668  644 
Revolving Credit Facility due 2023:
U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of 1.65%
—  154 
Japanese Yen denominated borrowings—Japanese Yen LIBOR at average floating rates of 1.50%
—  212 
5.0% Senior Notes due 2027—U.S. Dollar denominated
1,100  1,100 
5.0% Senior Notes due 2026—U.S. Dollar denominated
1,050  1,050 
2.875% Senior Notes due 2025—Euro denominated
492  471 
3.25% Senior Notes due 2025—Euro denominated
1,671  1,598 
3.5% Senior Notes due 2024—Euro denominated
—  701 
2.25% Senior Notes due 2028—Euro denominated
844  808 
2.875% Senior Notes due 2028—Euro denominated
834  — 
Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.05%
300  300 
Principal amount of debt 12,410  11,705 
Less: unamortized discount and debt issuance costs (71) (60)
Less: current portion (144) (100)
Long-term debt $ 12,195  $ 11,545 

16
Contractual maturities of long-term debt are as follows at September 30, 2020:
(in millions)
Remainder of 2020 36 
2021 146 
2022 446 
2023 1,699 
2024 1,867 
Thereafter 8,216 
12,410 
At September 30, 2020, there were bank guarantees totaling approximately £0.9 million (approximately $1.1 million) issued against the availability of the general banking facility.
Senior Secured Credit Facilities
At September 30, 2020, the Company’s Fourth Amended and Restated Credit Agreement, as amended (the “Credit Agreement”) provided financing through several senior secured credit facilities (collectively, the “senior secured credit facilities”) of up to approximately $7.6 billion, which consisted of $6.1 billion principal amounts of debt outstanding (as detailed in the table above), $1.5 billion of available borrowing capacity on the revolving credit facility and standby letters of credit.
On March 11, 2020, the Company entered into Amendment No. 7 to the Credit Agreement to borrow $900 million in additional U.S. Dollar denominated term A loans due 2023 (the “TLA-2 Loans”) and, on March 30, 2020, entered into Amendment No. 8 to the Credit Agreement to amend certain terms of the TLA-2 Loans. The TLA-2 Loans bear interest based on the U.S. Dollar LIBOR plus a margin ranging from 1.50% to 2.25%, with a U.S. Dollar LIBOR floor of 1.00% per annum. The proceeds from the TLA-2 Loans were used to repay outstanding revolving credit loans under the Company's senior secured credit facilities. On March 30, 2020, the Company prepaid $100 million of the TLA-2 loans.
Senior Notes
On June 24, 2020, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of the Company, completed the issuance and sale of €711,000,000 in gross proceeds of the Issuer’s 2.875% senior notes due 2028 (the “2.875% Notes”). The 2.875% Notes were issued pursuant to an Indenture, dated June 24, 2020, among the Issuer, U.S. Bank National Association, as trustee of the Notes, and certain subsidiaries of the Issuer as guarantors. The 2.875% Notes are unsecured obligations of the Issuer, will mature on June 15, 2028 and bear interest at the rate of 2.875% per year, with interest payable semiannually on June 15 and December 15 of each year, beginning on December 15, 2020. The Issuer may redeem the 2.875% Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to June 15, 2023 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 1.438% to 0.000%. The proceeds from the 2.875% Notes offering were used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024 (the “3.500% Notes”), including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the offering. The Issuer’s obligations with respect to the 3.500% Notes were discharged on the same day as the Issuer completed the issuance of the 3.500% Notes, and the 3.500% Notes were redeemed on July 9, 2020.
Restrictive Covenants
The Company’s debt agreements provide for certain covenants and events of default customary for similar instruments, including a covenant not to exceed a specified ratio of consolidated senior secured net indebtedness to Consolidated EBITDA, as defined in the senior secured credit facility agreement and a covenant to maintain a specified minimum interest coverage ratio. If an event of default occurs under any of the Company’s or the Company’s subsidiaries’ financing arrangements, the creditors under such financing arrangements will be entitled to take various actions, including the acceleration of amounts due under such arrangements, and in the case of the lenders under the revolving credit facility and term loans, other actions permitted to be taken by a secured creditor. The Company’s long-term debt arrangements contain other usual and customary restrictive covenants that, among other things, place limitations on the Company’s ability to declare dividends. At September 30, 2020, the Company was in compliance with the financial covenants under its debt agreements in all material respects and does not have material uncertainty about ongoing ability to meet the covenants of the Company’s credit arrangements.

17
Based on our current operating plan, and after considering the likely future impacts of COVID-19, we believe that our available cash and cash equivalents, future cash flows from operations and our ability to access funds under our revolving and other credit facilities will enable us to fund our operating requirements and capital expenditures and meet debt obligations for at least the next 12 months.

9. Stockholders’ Equity
Preferred Stock
The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued or outstanding as of September 30, 2020 or December 31, 2019.
Equity Repurchase Program

During the nine months ended September 30, 2020, the Company repurchased 2,106,403 shares of its common stock for approximately $321.4 million under the Repurchase Program. These amounts include 1,000,000 shares of our common stock repurchased from certain of the Company’s stockholders (the “Selling Stockholders”) in a private transaction for an aggregate purchase price of approximately $164.3 million. As of September 30, 2020, the Company has remaining authorization to repurchase up to approximately $1.0 billion of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program.
10. Restructuring
The Company has continued to take restructuring actions in 2020 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. These restructuring actions are expected to continue into 2021.
The following amounts were recorded for the restructuring plans:
(in millions)
Severance and
Related Costs
Facility
Exit Costs
Total
Balance at December 31, 2019 $ 64  $ 3  $ 67 
Expense, net of reversals
50  —  50 
Payments
(51) (1) (52)
Foreign currency translation and other
—  —  — 
Balance at September 30, 2020 $ 63  $ 2  $ 65 
Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects that the majority of the restructuring accruals at September 30, 2020 will be paid in 2020 and 2021.
11. Income Taxes

The effective income tax rate was (2.9)% and (1.4)% in the third quarter of 2020 and 2019, respectively, and 5.0% and 18.8% in the first nine months of 2020 and 2019, respectively. In the third quarter 2020, the U.S. Treasury Department issued final regulations regarding Foreign Derived Intangible Income (“FDII”) and Global Intangible Low-Taxed Income (“GILTI”). The Company has determined it will elect the GILTI high tax exception as allowed by the final regulations and will amend its 2018 and 2019 US Federal consolidated income tax returns resulting in a favorable impact of $24 million. The Company recorded this impact in the third quarter of 2020. The effective income tax rate in the third quarter and first nine months of 2020 and 2019 was also favorably impacted as a result of excess tax benefits recognized upon settlement of share-based compensation awards. For the third quarter of 2020 and 2019 this impact was $9 million and $3 million, respectively, and for the first nine months of 2020 and 2019 this impact was $35 million and $20 million, respectively. Additionally, the effective income tax rate in the first nine months of 2020 was unfavorably impacted by a $10 million discrete tax expense related to change in the measurement of the U.S. tax on undistributed foreign earnings.


18
In the first nine months of 2019 the U.S. Treasury Department issued final regulations on the transition tax and proposed regulations on FDII. While the final regulations related to the transition tax did not have a material impact on the Company, the proposed guidance on FDII had an unfavorable impact. Although the proposed guidance for FDII was not authoritative and subject to change in the regulatory review process, the Company reversed a portion of the tax benefit related to 2018 and recorded a tax expense of $20 million for this impact in the first nine months of 2019.
12. Comprehensive Income (Loss)
Below is a summary of the components of AOCI:
(in millions)
Foreign
Currency
Translation
Derivative
Instruments
Defined
Benefit
Plans
Income
Taxes
Total
Balance at December 31, 2019 $ (430) $ (21) $ (16) $ 156  $ (311)
Other comprehensive income (loss) before reclassifications
(62) (44) —  94  (12)
Reclassification adjustments
—  8  —  (2) 6 
Balance at September 30, 2020 $ (492) $ (57) $ (16) $ 248  $ (317)
Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item:
(in millions)
Affected Financial Statement
Line Item
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Derivative instruments:
Foreign exchange forward contracts
Revenues
$ 4  $ 2  $ 9  $ 3 
Foreign exchange forward contracts
Other expense (income), net
(1) —  (1) (6)
Total before income taxes
3  2  8  (3)
Income tax (benefit) expense
1  —  2  (1)
Total net of income taxes
$ 2  $ 2  $ 6  $ (2)

13. Segments
The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission-critical information, technology solutions and real-world insights and services to the Company’s life sciences customers. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market.
Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses related to integration activities and acquisitions. The Company also does not allocate depreciation and amortization or impairment charges to its segments. Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below:
19
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Revenues
Technology & Analytics Solutions
$ 1,207  $ 1,095  $ 3,433  $ 3,272 
Research & Development Solutions
1,400  1,466  4,076  4,317 
Contract Sales & Medical Solutions
179  208  552  604 
Total revenues
2,786  2,769  8,061  8,193 
Costs of revenue, exclusive of depreciation and amortization
Technology & Analytics Solutions
727  667  2,048  1,956 
Research & Development Solutions
925  1,007  2,811  2,924 
Contract Sales & Medical Solutions
148  178  469  519 
Total costs of revenue
1,800  1,852  5,328  5,399 
Selling, general and administrative expenses
Technology & Analytics Solutions
188  167  549  539 
Research & Development Solutions
184  172  544  529 
Contract Sales & Medical Solutions
14  15  44  45 
General corporate and unallocated
74  41  161  137 
Total selling, general and administrative expenses
460  395  1,298  1,250 
Segment profit
Technology & Analytics Solutions
292  261  836  777 
Research & Development Solutions
291  287  721  864 
Contract Sales & Medical Solutions
17  15  39  40 
Total segment profit
600  563  1,596  1,681 
General corporate and unallocated
(74) (41) (161) (137)
Depreciation and amortization
(319) (299) (943) (888)
Restructuring costs
(20) (19) (50) (45)
Total income from operations
$ 187  $ 204  $ 442  $ 611 

14. Earnings Per Share
The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive:
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Shares subject to performance conditions 1.1  1.3  1.2  1.3 
Shares subject to anti-dilutive stock-based awards 1.1  0.4  1.3  0.7 
Total shares excluded from diluted earnings per share 2.2  1.7  2.5  2.0 
The vesting of performance awards is contingent upon the achievement of certain performance targets. The performance awards are not included in diluted earnings per share until the performance targets have been met. Stock-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.


20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Statement for Forward-Looking Information
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (our “2019 Form 10-K”).
In addition to historical condensed consolidated financial information, the following discussion contains or incorporates by reference forward-looking statements within the meaning of the federal securities laws that are not historical facts but reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “forecasts,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. We assume no obligation to update any such forward-looking information to reflect actual results or changes in our outlook or the factors affecting such forward-looking information.

We caution you that any such forward-looking statements are further qualified by important factors that could cause our actual operating results to differ materially from those in the forward-looking statements, including without limitation, business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak or international conflict or other disruptions outside of our control; our ability to accurately model or forecast the impact of the spread and/or containment of COVID-19, among other sources of business interruption, on our operations and financial results; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the scope of prescription or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see Part I—Item 1A—“Risk Factors” in our 2019 Form 10-K, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “1Q 2020 Form 10-Q”).
Overview
IQVIA Holdings Inc. (“IQVIA,” the “Company,” “we,” “our” and/or “us”) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA applies human data science – leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science – to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, we deliver unique and actionable insights at the intersection of large scale analytics, transformative technology and extensive domain expertise as well as execution capabilities. With approximately 68,000 employees, we conduct operations in more than 100 countries.
21
Table of contents
We manage our business through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides critical information, technology solutions and real-world insights and services to our life science customers. Research & Development Solutions, which primarily serves biopharmaceutical customers, is engaged in research and development and provides clinical research and clinical trial services. Contract Sales & Medical Solutions provides contract sales to both biopharmaceutical customers and the broader healthcare market.

Recent Developments

As a result of the global spread of COVID-19 beginning in early March, we began to experience general business disruptions that impeded normal business activity including our ability to perform on-site monitoring and deliver offerings that rely on face-to-face interaction or in-person gatherings.
These disruptions have impacted all three of our reportable segments. We continue to see gradual improvement in the accessibility of clinical research sites in the Research & Development Solutions business. We are seeing a return to on-site monitoring visits and similar to last quarter, on-site visits exceeded the number of remote visits. In instances where sites remain physically inaccessible for clinical monitoring, remote monitoring and virtual solutions continue to be effective alternatives. Site start-up activities have increased during the quarter along with patient recruitment trends. Similarly, in our Technology & Analytics Solutions segment, the portion of our Real-World business that requires site monitoring activity also experienced limitations on site accessibility, which led to a reduction in the associated revenue. Within our Technology & Analytics Solutions segment, we have had very little interruption in data supply and demand. Our analytics and consulting businesses have performed well despite business development being hampered by lack of in-person interactions. Our Technology & Analytics solutions offerings that rely on face-to-face interactions or are dependent on in-person gatherings, events or conferences continue to experience disruption, and where we were unable to execute on our commitments due to COVID-19, we were not able to recognize the associated revenue in the period. Activity within the Contract Sales and Medical Solutions business continues to be more challenging due to a decline in sales rep visits, and physician attention diverted to the COVID-19 crisis.

We have accelerated and expanded a variety of cost containment actions to reduce the impact to profitability. We have activated business continuity plans, including remote delivery capabilities in technology and analytics, remote monitoring and virtual trials in Research & Development Solutions and virtual commercial activity with clients wherever possible. We anticipate an acceleration of business momentum when the crisis subsides as delayed trial activities will still need to be performed.

The Company continues to maintain strong liquidity. We do not expect COVID-19 to have a significant impact on our overall liquidity position and outlook. As of September 30, 2020, cash and cash equivalents were $1,464 million and the Company had no amounts drawn under its $1.5 billion revolving credit facility. At September 30, 2020, the Company was in compliance with the financial covenants under its debt agreements in all material respects and does not have material uncertainty about ongoing ability to meet the covenants of our credit arrangements. Based on the company's performance during the pandemic, continued robust demand for its offerings, solid liquidity, and strong free cash flow performance, the Company is lifting the temporary suspension of its share repurchase program.

To help ensure the safety and well-being of our employees, customers, partners and the broader community and continuity of our business operations, we continue to monitor health authority guidance on mitigating the spread of COVID-19 and managing positive cases. We manage our response to the pandemic through a combination of enterprise-wide and regional governance teams, with particular focus on the medical and scientific, information technology, human capital and financial impacts of the pandemic on our business. These teams met, and continue to meet, regularly as necessary based on the status of the pandemic. We closely monitor the impact of COVID-19 on our operations and report to our Board regularly on the progress of our response to the COVID-19 outbreak. We have established global workplace protocols that govern the return of our employees to our offices.
Sources of Revenue
Total revenues are comprised of revenues from the provision of our services. We do not have material product revenues.
22
Table of contents
Costs and Expenses
Our costs and expenses are comprised primarily of our costs of revenue, which include reimbursed expenses, and selling, general and administrative expenses. Costs of revenue include compensation and benefits for billable employees and personnel involved in production, data management and delivery, and the costs of acquiring and processing data for our information offerings; costs of staff directly involved with delivering technology-related services offerings and engagements, related accommodations and the costs of data purchased specifically for technology services engagements; costs related to facilities; costs related to training and expenses for information technology (“IT”), reimbursed expenses that are comprised principally of payments to investigators who oversee clinical trials and travel expenses for our clinical monitors and sales representatives; and other expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses. Selling, general and administrative expenses include costs related to sales, marketing, and administrative functions (including human resources, legal, finance and general management) for compensation and benefits, travel, professional services, facilities and training and expenses for IT.
Foreign Currency Translation
In the first nine months of 2020, approximately 35% of our revenues were denominated in currencies other than the United States dollar, which represents approximately 60 currencies. Because a large portion of our revenues and expenses are denominated in foreign currencies and our financial statements are reported in United States dollars, changes in foreign currency exchange rates can significantly affect our results of operations. The revenue and expenses of our foreign operations are generally denominated in local currencies and translated into United States dollars for financial reporting purposes. Accordingly, exchange rate fluctuations will affect the translation of foreign results into United States dollars for purposes of reporting our condensed consolidated results. As a result, we believe that reporting results of operations that exclude the effects of foreign currency rate fluctuations on certain financial results can facilitate analysis of period-to-period comparisons. This constant currency information assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results.
Consolidated Results of Operations
For information regarding our results of operations for Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions, refer to “Segment Results of Operations” later in this section.
Revenues
Three Months Ended September 30,
Change
(in millions)
2020 2019
$
%
Revenues
$ 2,786  $ 2,769  $ 17  0.6  %
For the third quarter of 2020, our revenues increased $17 million, or 0.6%, as compared to the same period in 2019. This increase was comprised of constant currency revenue decline of approximately $4 million, or 0.1%. The constant currency revenue decline was comprised of a $75 million decrease in Research & Development Solutions and a $30 million decrease in Contract Sales & Medical Solutions, offset by a $101 million increase in Technology & Analytics Solutions.

Nine Months Ended September 30,
Change
(in millions)
2020 2019
$
%
Revenues
$ 8,061  $ 8,193  $ (132) (1.6) %
For the first nine months of 2020, our revenues decreased $132 million, or 1.6%, as compared to the same period in 2019. This decrease was comprised of constant currency revenue decline of approximately $100 million, or 1.2%. The constant currency revenue decline was comprised of a $232 million decrease in Research & Development Solutions and a $50 million decrease in Contract Sales & Medical Solutions, offset by a $182 million increase in Technology & Analytics Solutions.
See Part I—Item 2—“Recent Developments" in this Quarterly Report on Form 10-Q for a discussion of the impact from COVID-19 on our business activity.


23
Costs of Revenue, exclusive of Depreciation and Amortization
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Costs of revenue, exclusive of depreciation and amortization
$ 1,800  $ 1,852  $ 5,328  $ 5,399 
% of revenues
64.6  % 66.9  % 66.1  % 65.9  %
The $52 million decrease in costs of revenues, exclusive of depreciation and amortization, for the three months ended September 30, 2020 as compared to the same period in 2019 included a constant currency decrease of approximately $62 million, or 3.3%. The constant currency decrease consisted of a $82 million decrease in Research & Development Solutions and a $32 million decrease in Contract Sales & Medical Solutions, offset by a $52 million increase in Technology & Analytics Solutions.
The $71 million decrease in costs of revenues, exclusive of depreciation and amortization, for the nine months ended September 30, 2020 as compared to the same period in 2019 included a constant currency decrease of approximately $19 million, or 0.4%. The constant currency decrease consisted of a $73 million decrease in Research & Development Solutions, a $49 million decrease in Contract Sales & Medical Solutions, offset by a $103 million increase in Technology & Analytics Solutions.
Selling, General and Administrative Expenses
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Selling, general and administrative expenses
$ 460  $ 395  $ 1,298  $ 1,250 
% of revenues
16.5  % 14.3  % 16.1  % 15.3  %
The $65 million increase in selling, general and administrative expenses for the three months ended September 30, 2020 as compared to the same period in 2019 included a constant currency increase of approximately $64 million, or 16.2%. The constant currency increase primarily consisted of a $32 million increase in general corporate and unallocated expenses, a $13 million increase in Research & Development Solutions, a $20 million increase in Technology & Analytics Solutions, offset by a $1 million decrease in Contract Sales & Medical Solutions.
The $48 million increase in selling, general and administrative expenses for the nine months ended September 30, 2020 as compared to the same period in 2019 included a constant currency increase of approximately $62 million, or 5.0%. The constant currency increase primarily consisted of a $25 million increase in general corporate and unallocated expenses, a $17 million increase in Technology & Analytics Solutions, a $21 million increase in Research & Development Solutions, offset by a $1 million decrease in Contract Sales & Medical Solutions.
Depreciation and Amortization
Three Months Ended September 30, Nine Months Ended September 30,
(in millions)
2020 2019 2020 2019
Depreciation and amortization 319  299  943  888 
% of revenues
11.5  % 10.8  % 11.7  % 10.8  %

The $20 million and $55 million increases in depreciation and amortization in the three and nine months ended September 30, 2020, respectively, as compared to the same periods in 2019 was primarily due to higher intangible asset balances as a result of acquisitions occurring in 2019, increased amortization due to higher capitalized software balances, and accelerated depreciation on an internal-use software asset in the first quarter of 2020.
24
Restructuring Costs
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Restructuring costs $ 20  $ 19  $ 50  $ 45 
The restructuring costs incurred during 2020 were due to ongoing efforts to streamline our global operations. The remaining actions under these plans are expected to occur throughout 2020 and into 2021 and are expected to consist of consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements.
Interest Income and Interest Expense
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Interest income $ (1) $ (3) $ (4) $ (7)
Interest expense $ 100  $ 114  $ 314  $ 338 
Interest income includes interest received primarily from bank balances and investments.

Interest expense during the three and nine months ended September 30, 2020 was lower than the same periods in 2019 due to lower interest rates attributed to lower LIBOR rates and the redemption of the $800 million of 4.875% senior notes due 2023, partially offset by an increase in the average debt outstanding.
Loss on Extinguishment of Debt

Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Loss on extinguishment of debt $ —  $ 24  $ 12  $ 24 
During the second quarter of 2020, we recognized loss on extinguishment of debt for fees and expenses incurred related to the refinancing of our 3.500% senior notes due 2024.
Other Income, Net
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Other income, net $ (14) $ —  $ (59) $ — 
Other income, net for the three months ended September 30, 2020 increased as compared to the same period in the prior year, primarily due to a gain on investments in mutual funds.
Other income, net for the nine months ended September 30, 2020 increased as compared to the same periods in the prior year, primarily due to a decrease in fair value of acquisition-related contingent consideration, mark-to-market gains on equity securities, a decrease in foreign currency losses, and a gain on investments in mutual funds.
25
Income Tax Expense
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Income tax (benefit) expense $ (3) $ (1) $ 9  $ 48 

Our effective income tax rate was (2.9)% and (1.4)% in the third quarter of 2020 and 2019, respectively, and 5.0% and 18.8% in the first nine months of 2020 and 2019, respectively. In the third quarter 2020, the U.S. Treasury Department issued final regulations regarding Foreign Derived Intangible Income (“FDII”) and Global Intangible Low-Taxed Income (“GILTI”). We have determined we will elect the GILTI high tax exception as allowed by the final regulations and will amend its 2018 and 2019 US Federal consolidated income tax returns resulting in a favorable impact of $24 million. We recorded this impact in the third quarter of 2020. Our effective income tax rate in the third quarter and first nine months of 2020 and 2019 was also favorably impacted as a result of excess tax benefits recognized upon settlement of share-based compensation awards. For the third quarter of 2020 and 2019 this impact was $9 million and $3 million, respectively, and for the first nine months of 2020 and 2019 this impact was $35 million and $20 million, respectively. Additionally, our effective income tax rate in the first nine months of 2020 was unfavorably impacted by a $10 million discrete tax expense related to change in the measurement of the U.S. tax on undistributed foreign earnings.

In the first nine months of 2019, the U.S. Treasury Department issued final regulations on the transition tax and proposed regulations on FDII. While the final regulations related to the transition tax did not have a material impact on us, the proposed guidance on FDII had an unfavorable impact. Although the proposed guidance for FDII was not authoritative and subject to change in the regulatory review process, we reversed a portion of the tax benefit related to 2018 and recorded a tax expense of $20 million for this impact in the first nine months of 2019.
Equity in Earnings of Unconsolidated Affiliates
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Equity in earnings (loss) of unconsolidated affiliates $ 3  $ (1) $ 8  $ (1)
Equity in earnings of unconsolidated affiliates for the three and nine months ended September 30, 2020 increased as compared to the same period in the prior year, primarily related to higher earnings from our investment in NovaQuest Pharma Opportunities Fund III.
Net Income Attributable to Non-controlling Interests
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2020 2019 2020 2019
Net income attributable to non-controlling interests $ (7) $ (12) $ (18) $ (32)
Net income attributable to non-controlling interests primarily included Quest Diagnostics Incorporated’s interest in Q2 Solutions.

26
Segment Results of Operations
The Company’s revenues and profit by segment are as follows:
Three Months Ended September 30, 2020 and 2019
Segment Revenues Segment Profit
(in millions) 2020 2019 2020 2019
Technology & Analytics Solutions $ 1,207  $ 1,095  $ 292  $ 261 
Research & Development Solutions 1,400  1,466  291  287 
Contract Sales & Medical Solutions 179  208  17  15 
Total 2,786  2,769  600  563 
General corporate and unallocated (74) (41)
Depreciation and amortization (319) (299)
Restructuring costs (20) (19)
Consolidated $ 2,786  $ 2,769  $ 187  $ 204 
 
Nine Months Ended September 30, 2020 and 2019
Segment Revenues Segment Profit
(in millions) 2020 2019 2020 2019
Technology & Analytics Solutions $ 3,433  $ 3,272  $ 836  $ 777 
Research & Development Solutions 4,076  4,317  721  864 
Contract Sales & Medical Solutions 552  604  39  40 
Total 8,061  8,193  1,596  1,681 
General corporate and unallocated (161) (137)
Depreciation and amortization (943) (888)
Restructuring costs (50) (45)
Consolidated $ 8,061  $ 8,193  $ 442  $ 611 
Certain costs are not allocated to our segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses related to integration activities and acquisitions. We also do not allocate depreciation and amortization or impairment charges to our segments.
Technology & Analytics Solutions
Three Months Ended September 30, Change
(in millions) 2020 2019 $ %
Revenues $ 1,207  $ 1,095  $ 112  10.2 
Costs of revenue, exclusive of depreciation and amortization 727  667  60  9.0 
Selling, general and administrative 188  167  21  12.6 
Segment profit $ 292  $ 261  $ 31  11.9 

Nine Months Ended September 30, Change
(in millions) 2020 2019 $ %
Revenues $ 3,433  $ 3,272  $ 161  4.9 
Costs of revenue, exclusive of depreciation and amortization 2,048  1,956  92  4.7 
Selling, general and administrative 549  539  10  1.9 
Segment profit $ 836  $ 777  $ 59  7.6 

27
Revenues

Technology & Analytics Solutions’ revenues were $1,207 million for the third quarter of 2020, an increase of $112 million, or 10.2%, over the same period in 2019. This increase was comprised of constant currency revenue growth of approximately $101 million, or 9.2%.

Technology & Analytics Solutions’ revenues were $3,433 million for the first nine months of 2020, an increase of $161 million, or 4.9%, over the same period in 2019. This increase was comprised of constant currency revenue growth of approximately $182 million, or 5.6%.

The constant currency growth for the three and nine months ended September 30, 2020 resulted primarily from revenue growth in the Americas and Europe and Africa region. The revenue growth in these regions was driven by higher real-world and analytical services. See Part I—Item 2—“Recent Developments" in this Quarterly Report on Form 10-Q for a discussion of the impact from COVID-19 on Technology & Analytics Solutions business activity.
Costs of Revenue, exclusive of Depreciation and Amortization
Technology & Analytics Solutions’ costs of revenue increased $60 million, or 9.0%, in the third quarter of 2020 over the same period in 2019. This increase included a constant currency increase of approximately $52 million, or 7.8%.
Technology & Analytics Solutions’ costs of revenue increased $92 million, or 4.7%, in the first nine months of 2020 over the same period in 2019. This increase included a constant currency increase of approximately $103 million, or 5.3%.
The constant currency increase for the three and nine months ended September 30, 2020 was primarily due to an increase in compensation and related expenses to support revenue growth.
Selling, General and Administrative Expenses
Technology & Analytics Solutions’ selling, general and administrative expenses increased $21 million, or 12.6%, in the third quarter of 2020 as compared to the same period in 2019, which included a constant currency increase of approximately $20 million, or 12.0%.
Technology & Analytics Solutions’ selling, general and administrative expenses increased $10 million, or 1.9%, in the first nine months of 2020 as compared to the same period in 2019, which included a constant currency increase of approximately $17 million, or 3.2%.
The constant currency increase for the three and nine months ended September 30, 2020 was primarily related to an increase in compensation and related expenses.
Research & Development Solutions
Three Months Ended September 30, Change
(in millions)
2020 2019
$
%
Revenues
$ 1,400  $ 1,466  $ (66) (4.5) %
Costs of revenue, exclusive of depreciation and amortization
925  1,007  (82) (8.1) %
Selling, general and administrative expenses
184  172  12  7.0  %
Segment profit
$ 291  $ 287  $ 4  1.4  %

Nine Months Ended September 30,
Change
(in millions)
2020 2019
$
%
Revenues
$ 4,076  $ 4,317  $ (241) (5.6) %
Costs of revenue, exclusive of depreciation and amortization
2,811  2,924  (113) (3.9) %
Selling, general and administrative expenses
544  529  15  2.8  %
Segment profit
$ 721  $ 864  $ (143) (16.6) %
28
Backlog
Research & Development Solutions’ contracted backlog increased from $19.0 billion at December 31, 2019 to $21.7 billion at September 30, 2020 and we expect approximately $5.8 billion of this backlog to convert to revenue in the next twelve months.
Revenues
Research & Development Solutions’ revenues were $1,400 million in the third quarter of 2020, a decrease of $66 million, or 4.5%, over the same period in 2019. This decrease was comprised of constant currency revenue decline of approximately $75 million, or 5.1%.
Research & Development Solutions’ revenues were $4,076 million in the first nine months of 2020, a decrease of $241 million, or 5.6%, over the same period in 2019. This decrease was comprised of constant currency revenue decline of approximately $232 million, or 5.4%.
The constant currency decline for the three and nine months ended September 30, 2020 primarily included volume-related decreases in clinical services and lab testing. See Part I—Item 2—“Recent Developments" in this Quarterly Report on Form 10-Q for a discussion of the impact from COVID-19 on Research & Development Solutions business activity.
Costs of Revenue, exclusive of Depreciation and Amortization
Research & Development Solutions’ costs of revenue decreased $82 million, or 8.1%, in the third quarter of 2020 over the same period in 2019. This decrease included a constant currency decrease of approximately $82 million, or 8.1%.
Research & Development Solutions’ costs of revenue decreased $113 million, or 3.9%, in the first nine months of 2020 over the same period in 2019. This decrease included a constant currency decrease of approximately $73 million, or 2.5%.
The constant currency decrease for the three and nine months ended September 30, 2020 was primarily related to a decrease in compensation and related expenses as a result of reduced volume in clinical services and lab testing impacted by COVID-19.
Selling, General and Administrative Expenses
Research & Development Solutions’ selling, general and administrative expenses increased $12 million, or 7.0%, in the third quarter of 2020 as compared to the same period in 2019, which included a constant currency increase of approximately $13 million, or 7.6%.
Research & Development Solutions’ selling, general and administrative expenses increased $15 million, or 2.8%, in the first nine months of 2020 as compared to the same period in 2019, which included a constant currency increase of approximately $21 million, or 4.0%.
The constant currency increase for the three and nine months ended September 30, 2020 was primarily related to an increase in compensation and related expenses.
Contract Sales & Medical Solutions
Three Months Ended September 30,
Change
(in millions)
2020 2019
$
%
Revenues
$ 179  $ 208  $ (29) (13.9) %
Costs of revenue, exclusive of depreciation and amortization
148  178  (30) (16.9) %
Selling, general and administrative expenses
14  15  (1) (6.7)
Segment profit
$ 17  $ 15  $ 2  13.3  %

29
Nine Months Ended September 30,
Change
(in millions)
2020 2019
$
%
Revenues $ 552  $ 604  $ (52) (8.6) %
Costs of revenue, exclusive of depreciation and amortization
469  519  (50) (9.6) %
Selling, general and administrative expenses 44  45  (1) (2.2) %
Segment profit $ 39  $ 40  $ (1) (2.5) %
Revenues

Contract Sales & Medical Solutions’ revenues were $179 million in the third quarter of 2020, a decrease of $29 million, or 13.9%, over the same period in 2019. This decrease included a constant currency revenue decline of approximately $30 million, or 14.4%.

Contract Sales & Medical Solutions’ revenues were $552 million in the first nine months of 2020, a decrease of $52 million, or 8.6%, over the same period in 2019. This decrease included a constant currency revenue decline of approximately $50 million, or 8.3%.

The constant currency decline for three and nine months ended September 30, 2020 was largely due to a volume decrease in the Americas region, partially offset by a volume increase in the Asia-Pacific regions. See Part I—Item 2—“Recent Developments" in this Quarterly Report on Form 10-Q for a discussion of the impact from COVID-19 on Contract Sales & Medical Solutions business activity.
Costs of Revenue, exclusive of Depreciation and Amortization
Contract Sales & Medical Solutions’ costs of revenue decreased $30 million, or 16.9%, in the third quarter of 2020 as compared to the same period in 2019. This decrease included a constant currency decrease of approximately $32 million, or 18.0%.
Contract Sales & Medical Solutions’ costs of revenue decreased $50 million, or 9.6%, in the first nine months of 2020 as compared to the same period in 2019. This decrease included a constant currency decline of approximately $49 million, or 9.4%.
The constant currency decrease for the three and nine months ended September 30, 2020 was due to a decrease in compensation and related expenses as a result of reduced volume in the Americas region.
Selling, General and Administrative Expenses
Contract Sales & Medical Solutions’ selling, general and administrative expenses remained flat for the three and nine months ended September 30, 2020 as compared to the same period in 2019.

Liquidity and Capital Resources
Overview
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. Our principal source of liquidity is operating cash flows. In addition to operating cash flows, other significant factors that affect our overall management of liquidity include: capital expenditures, acquisitions, investments, debt service requirements, dividends, equity repurchases, adequacy of our revolving and other credit facilities and access to the capital markets. We do not expect to have a significant impact on our overall liquidity position and outlook as a result of COVID-19.
We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which those funds can be accessed on a cost-effective basis. The repatriation of cash balances from certain of our subsidiaries could have adverse tax consequences; however, those balances are generally available without legal
30
restrictions to fund ordinary business operations. We have and expect to transfer cash from those subsidiaries to the United States and to other international subsidiaries when it is cost effective to do so.
We had a cash balance of $1,464 million at September 30, 2020 ($780 million of which was in the United States), an increase from $837 million at December 31, 2019. We also had $1.5 billion of additional available borrowings under our revolving credit facility at September 30, 2020.

Based on our current operating plan, and after considering the likely future impacts of COVID-19, we believe that our available cash and cash equivalents, future cash flows from operations and our ability to access funds under our revolving and other credit facilities will enable us to fund our operating requirements and capital expenditures and meet debt obligations for at least the next 12 months. We regularly evaluate our debt arrangements, as well as market conditions, and from time to time we may explore opportunities to modify our existing debt arrangements or pursue additional financing arrangements that could result in the issuance of new debt securities by us or our affiliates. We may use our existing cash, cash generated from operations or dispositions of assets or businesses and/or proceeds from any new financing arrangements or issuances of debt or equity securities to repay or reduce some of our outstanding obligations, to repurchase shares from our stockholders or for other purposes. As part of our ongoing business strategy, we also continually evaluate new acquisition, expansion and investment possibilities or other strategic growth opportunities, as well as potential dispositions of assets or businesses, as appropriate, including dispositions that may cause us to recognize a loss on certain assets. Should we elect to pursue any such transaction, we may seek to obtain debt or equity financing to facilitate those activities. Our ability to enter into any such potential transactions and our use of cash or proceeds is limited to varying degrees by the terms and restrictions contained in our existing debt arrangements. We cannot provide assurances that we will be able to complete any such financing arrangements or other transactions on favorable terms or at all.
Equity Repurchase Program

When the COVID-19 outbreak became a pandemic in March, the Company temporarily suspended share repurchase activity. Based on the Company's performance during the pandemic, continued robust demand for its offerings, solid liquidity, and strong free cash flow performance, the Company is lifting the temporary suspension of its share repurchase program. During the nine months ended September 30, 2020, we repurchased 2,106,403 shares of our common stock for approximately $321.4 million under the Repurchase Program. These amounts include 1,000,000 shares of our common stock repurchased from certain Selling Stockholders in a private transaction for an aggregate purchase price of approximately $164.3 million. See Note 9 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding the Repurchase Program.
As of September 30, 2020, we have remaining authorization to repurchase up to approximately $1.0 billion of our common stock under the Repurchase Program. In addition, from time to time, we have repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program.
Debt
Senior Secured Facilities

On March 11, 2020, we entered into an amendment to the Credit Agreement to borrow $900 million in additional U.S. Dollar denominated term A loans due 2023. The proceeds from the additional term A loans were used to repay outstanding revolving credit loans under our senior secured credit facilities. On March 30, 2020, we prepaid $100 million of the additional term A loans. See Note 8 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding our credit arrangements.
Senior Notes
On June 24, 2020, we completed the issuance and sale of €711,000,000 in gross proceeds of the Issuer’s 2.875% senior notes due 2028 (the “2.875% Notes”). The proceeds from the 2.875% Notes offering were used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024 (the “3.500% Notes”), including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering. See Note 8 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding our credit arrangements.
As of September 30, 2020, we had $12.4 billion of total indebtedness, excluding $1.5 billion of additional available borrowings under our revolving credit facility.
31
Our long-term debt arrangements contain customary restrictive covenants and, as of September 30, 2020, we believe we were in compliance with our restrictive covenants in all material respects. We do not have material uncertainty about ongoing ability to meet the covenants of our credit arrangements.
Nine months ended September 30, 2020 and 2019
Cash Flow from Operating Activities
Nine Months Ended September 30,
(in millions) 2020 2019
Net cash provided by operating activities $ 1,209  $ 834 

Cash provided by operating activities increased $375 million during the first nine months of 2020 as compared to the same period in 2019. The increase was primarily due to an increase in cash collections from clients and the impact of COVID-19 resulting in a decrease in accounts receivable and unbilled services compared to an increase in the prior period ($495 million), offset by less cash from other operating assets and liabilities ($99 million) and lower cash-related net income ($21 million).
Cash Flow from Investing Activities
Nine Months Ended September 30,
(in millions) 2020 2019
Net cash used in investing activities $ (560) $ (910)
Cash used in investing activities decreased $350 million during the first nine months of 2020 as compared to the same period in 2019. This decrease was primarily driven by lower cash used for the acquisition of businesses, net of cash acquired ($343 million).
Cash Flow from Financing Activities
Nine Months Ended September 30,
(in millions) 2020 2019
Net cash (used in) provided by financing activities $ (19) $ 67 
Cash provided by financing activities decreased $86 million during the first nine months of 2020 as compared to the same period in 2019. The decrease in cash provided by financing activities was primarily due to a decrease in cash provided by proceeds from revolving credit facilities, net of repayments ($140 million), a decrease in cash provided by proceeds from debt issuances, net of repayments and debt issuance costs ($212 million), less cash proceeds from employee stock option plans ($58 million), offset by less cash used to repurchase common stock ($333 million).
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Contractual Obligations and Commitments
We have various contractual obligations, which are recorded as liabilities in our consolidated financial statements.
With the exception of new senior secured credit facilities and senior note disclosed in Note 8 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes, outside of the ordinary course of business, to our contractual obligations as previously disclosed in our 2019 Form 10-K.
Application of Critical Accounting Policies
There have been no material changes to our critical accounting policies as previously disclosed in our 2019 Form 10-K.
32
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our 2019 Form 10-K.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of such date, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33
Table of contents
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
We are party to legal proceedings incidental to our business. While the outcome of these matters could differ from management’s expectations, we do not believe that the resolution of these matters is reasonably likely to have a material adverse effect to our financial statements.
Item 1A. Risk Factors

For a discussion of the risks relating to our business, see Part I—Item 1A—“Risk Factors” of our 2019 Form 10-K, as updated in our 1Q 2020 Form 10-Q. There have been no material changes from the risk factors previously disclosed in our 1Q 2020 Form 10-Q.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Securities
Not applicable.
Use of Proceeds from Registered Securities
Not applicable.
Purchases of Equity Securities by the Issuer
On October 30, 2013, our Board approved the Repurchase Program authorizing the repurchase of up to $125.0 million of either our common stock or vested in-the-money employee stock options, or a combination thereof. Our Board increased the stock repurchase authorization under the Repurchase Program with respect to the repurchase of our common stock by $600 million, $1.5 billion, $2.0 billion, $1.5 billion and $2.0 billion in 2015, 2016, 2017, 2018 and 2019, respectively, which increased the total amount that has been authorized under the Repurchase Program to $7.725 billion. The Repurchase Program does not obligate us to repurchase any particular amount of common stock or vested in-the-money employee stock options, and it may be modified, suspended or discontinued at any time. The timing and amount of repurchases are determined by our management based on a variety of factors such as the market price of our common stock, our corporate requirements, and overall market conditions. Purchases of our common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Repurchase Program for common stock does not have an expiration date.
From inception of the Repurchase Program through September 30, 2020, we have repurchased a total of $6.7 billion of our securities under the Repurchase Program.

During the nine months ended September 30, 2020, we repurchased 2,106,403 shares of our common stock for approximately $321.4 million under the Repurchase Program. These amounts include 1,000,000 shares of our common stock repurchased from certain Selling Stockholders in a private transaction for an aggregate purchase price of approximately $164.3 million. See Note 9 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding the Repurchase Program.
As of September 30, 2020, we have remaining authorization to repurchase up to approximately $1.0 billion of our common stock under the Repurchase Program. In addition, from time to time, we have repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program.
Since the merger between Quintiles and IMS Health, we have repurchased 65.0 million shares of our common stock at an average market price per share of $96.64 for an aggregate purchase price of $6.3 billion both under and outside of the Repurchase Program. This includes shares withheld from employees to satisfy certain tax obligations due in connection with grants of stock under the Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan (the “Plan”). The Plan provides for the withholding of shares to satisfy tax obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item.
34
Table of contents
The following table summarizes the monthly equity repurchase program activity for the three months ended September 30, 2020 and the approximate dollar value of shares that may yet be purchased pursuant to the Repurchase Program.
(in millions, except per share data) Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
July 1, 2020 — July 31, 2020 —  —  —  $ 1,019 
August 1, 2020 — August 30, 2020 —  —  —  $ 1,019 
September 1, 2020 — September 30, 2020 —  —  —  $ 1,019 
—  — 

35
Table of contents
Item 6. Exhibits
The exhibits below are filed or furnished as a part of this report and are incorporated herein by reference.
Incorporated by Reference
Exhibit
Number 		Exhibit Description Filed
Herewith 		Form File No. Exhibit Filing Date
10.1 X
31.1 X
31.2 X
32.1 X
32.2 X
101 Interactive Data Files Pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Statements of Income (unaudited), (ii) Condensed Consolidated Statements of Comprehensive Income (unaudited), (iii) Condensed Consolidated Balance Sheets (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited), (v) Condensed Consolidated Statements of Stockholders’ Equity and (vi) Notes to Condensed Consolidated Financial Statements (unaudited). The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X
104 Cover Page Interactive Data File. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X

36
Table of contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized on October 22, 2020.
IQVIA HOLDINGS INC.
/s/ Ronald E. Bruehlman
Ronald E. Bruehlman
Executive Vice President and Interim Chief Financial Officer
(On behalf of the Registrant and as Principal Financial Officer)

37


Exhibit 10.1




LOGO21.GIF
July 28, 2020


Dear Ron,

We want to welcome you to IQVIA™
On behalf of IQVIA, The Human Data Science Company™, we are pleased to extend an
offer of employment for you to join our global team.

IQVIA's talented professionals across the globe help clients create solutions that drive healthcare forward to advance clinical outcomes and commercial performance. Our employees are passionate about channeling their insights, commercial and scientific depth, and executional expertise to help improve health outcomes for patients around the globe.

This packet includes a summary page outlining the major components of your offer of employment. Recognizing that our people are our most important asset, we offer a comprehensive benefits package, which includes medical, dental and vision coverage, short-term and long-term disability, retirement plan, life insurance, tuition reimbursement, and more. Additional information is endorsed, and these benefits will be discussed in greater detail during your department orientation.

To accept this offer of employment, please complete and return the enclosed forms within five business days.

We look forward to receiving your written acceptance to join our team. We are really excited to welcome you to IQVIA. Whatever your career goals, we are here to ensure you get there!

Please join us to move healthcare forward. Together.


Kind regards,
/s/ Trudy Stein

Trudy Stein
EVP & CHRO




LOGO21.GIF
Name: Ron Bruehlman
* Date of offer: July 28. 2020
* Your start date: August 1, 2020
* Position Title / Level: EVP, interim Chief Financial Officer
* Department: US20 Finance
* Location: WFH/Parsippany, NJ
* Manager / Title: Ari Bousbib
* FT / PT Status: Full Time
* Base Salary: $860,000 (annualized). Pay is semi-monthly
*
Annual Incentive Target: 100% of your annual base salary. Your manager will communicate performance parameters at a later date. Incentive payouts are not guaranteed and are prorated based on start date and time worked. Your start date must occur on or before September 30 to be eligible to participate in an incentive plan for the year.
*
Long-Term Incentive Award: As a part of your new hire offer, you have been nominated for a one­ time Restricted Stock ( Unit award (the “One-Time RSU”) with a nominal value of $2,700,000 to be effective August 3, 2020 (the “Grant Date”) subject to final approval by the Leadership Development and Compensation Committee (the “Committee”) of the Board of Directors of IQVIA Holdings Inc.
IQVIA will determine the number of One-Time RSUs by dividing the nominal value of $2,700,000 by the closing price of a share of IQVIA common stock as of the Grant Date. An RSU is the promise of a share of stock on a future date (the “Vesting Date”). It is “restricted” because until it vests, you cannot sell it and you have no voting rights. It is a “unit” because the share under1ying the unit isn't transferred to you until the Vesting Date. The One-Time RSUs will vest in equal installments on each of the first three anniversaries of the Grant Date. If you leave our employment for any reason, you will forfeit any One-Time RSUs that are unvested at that time.
One-Time RSUs approved by the Committee will be subject to the various terms and conditions of the IQVIA Holdings Inc. 2017 Incentive and Stock Award Plan (the “Plan”) and the grant agreement, including provisions regarding vesting and forfeiture.
Your One-Time RSU is contingent upon proper execution of a Confidentiality and Restrictive Covenant Agreement (CRCA) and Work Product Assignment Agreement (WPAA) relating to the protection of IQVIA intellectual property, including confidentiality, ownership, non-competition and non-solicitation. These documents will be provided to you separately.
*
Time off during calendar year of 2020
    Vacation Days:        Discretionary Time-off
    Company Holidays:    10 Days
This offer of employment with IQVIA™ is contingent upon (a) receipt of acceptable references and credential qualifications; (b) having no existing restrictions which would prohibit you from accepting this offer or, by working for IQVIA, would infringe the rights of others; (c) your signing and returning the attached Confidentiality & Policy Agreement as well as the Third Party Confidential Information Notice; and (d) receipt of proof of your eligibility to work in the United States as required by the Immigration



Reform and Control Act of 1986. You will need to bring certain documents on your first day of employment (by law, no later than three business days from your start date). Please refer to the enclosed list of acceptable documents for Employment Eligibility Verification.
This offer letter shall not be construed as constituting a contract for employment, or otherwise set forth a length of employment. You are an employee at-will, which means that either you or IQVIA may end the employment relationship without cause or notice.
Upon your start date, any agreement(s) between you and the company with regard to your current role as a senior advisor to the CEO will terminate and will no longer be in force.
I accept the terms of this offer as stated and will start on:
/s/ Ronald E. Bruehlman 8/1/2020
Sign to Accept State Date
Approved:
/s/ Trudy Stein
Name: Trudy Stein




Exhibit 31.1
CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Ari Bousbib, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IQVIA Holdings Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 22, 2020
/s/ Ari Bousbib
Ari Bousbib
Chairman, Chief Executive Officer and President
(Principal Executive Officer)



Exhibit 31.2
CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Ronald E. Bruehlman, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IQVIA Holdings Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 22, 2020
/s/ Ronald E. Bruehlman
Ronald E. Bruehlman
Executive Vice President and Interim Chief Financial Officer
(On behalf of the Registrant and as Principal Financial Officer)





Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Ari Bousbib, Chairman, Chief Executive Officer and President of IQVIA Holdings Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.
Date: October 22, 2020
/s/ Ari Bousbib
Ari Bousbib
Chairman, Chief Executive Officer and President
(Principal Executive Officer)
This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Ronald E. Bruehlman, Executive Vice President and Interim Chief Financial Officer of IQVIA Holdings Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.
Date: October 22, 2020
/s/ Ronald E. Bruehlman
Ronald E. Bruehlman
Executive Vice President and Interim Chief Financial Officer
(On behalf of the Registrant and as Principal Financial Officer)
This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.